Alva Therapeutics, Inc. has announced that Jesper Høiland has joined its Board of Directors as the company continues advancing its oral incretin secretagogue therapy for people living with Type 2 diabetes and obesity. The appointment brings one of the most experienced leaders in the metabolic disease space to Alva during a critical stage of its clinical progress.
Health Technology Insights: SEI Names Patrick Donegan as Managing Director of Philadelphia Office
Jesper Høiland spent more than thirty years at Novo Nordisk in a series of senior roles, eventually taking on global leadership responsibilities as an Executive Vice President and President. During his long tenure, he played a central part in bringing several major diabetes therapies to market and helped guide the company through periods of major growth. He later served as President and CEO of Radius Health and held the role of Global Commercial Officer at Ascendis Pharma, where he directed large scale commercial operations. He currently chairs SciBase Holding AB and sits on the boards of ALK Abelló A S, Flen Health SA and Allarity Therapeutics.
Health Technology Insights: PDS Health, Univ. of Michigan Partner to Launch Epic EHR System
Mir Imran, Chief Executive Officer and Chairman of the Board at Alva Therapeutics, expressed strong enthusiasm for the appointment. He noted that Høiland’s background in leading major drug launches in diabetes will be especially important as Alva advances its own therapeutic candidate through development. Imran said that Høiland’s strategic insight will support the company as it prepares for the next stages of research and clinical planning.
Speaking about his decision to join the Board, Høiland said the science behind Alva Therapeutics impressed him from the start. He believes the company’s approach represents a major step forward in how Type 2 diabetes and obesity could be treated in the future. According to him, the potential impact of the therapy is significant and may offer an option unlike anything currently available to patients.
Health Technology Insights: Exxat Teams with Continuum to Boost Clinical Education
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
